Fear of MRSA - Potential for future disaster

Burns

Volumn 24, Issue 2, 1998, Pages 99-103

  Holder, Ian Alan ^a   Neely, Alice N ^a  

^a SHRINERS HOSPITALS FOR CHILDREN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GENTAMICIN; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; DRUG USE; HUMAN; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; REVIEW;

EID: 0032029183     PISSN: 03054179     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0305-4179(97)00109-5     Document Type: Article

References (68)

1. [1] Lyon, B. R. and Skurray, R., Antimicrobial resistance of Staphylococcus aureus: genetic basis. Microbiol. Rev., 1987, 51, 88-134.
2. [2] Chambers, H. F., Methicillin-resistant staphyloccci. Clin. Microbiol. Rev., 1988, 1, 173-186.
3. [3] Panlilio, A. L., Culver, D. H. and Gaynes, R. P. et al., Methicillin-resistant Staphylococcus aureus in US hospitals, 1975-1991. Infect. Control Hosp. Epidem., 1992, 13, 582-586.
4. [4] Luterman, A., Dasco, C. C. and Curreri, P. W., Infections in burn patients. Am. J. Med., 1986, 81, 45-48.
5. [5] Heggers, J. P., Phillips, L. G. and Boertman, J. A. et al., The epidemiology of methicillin-resistant Staphylococcus aureus in a burn center. J. Burn Care Rehab., 1988, 9, 610-612.
6. [6] Taylor, G. D., Kibsey, P., Kirkland, T., Burroughs, E. and Tredget, E., Predominance of staphylococcal organisms in infections occurring in a burns intensive care unit. Burns, 1992, 18, 332-335.
7. [7] Boyce, J. M., Methicillin-resistant Staphylococcus aureus: detection epidemiology and control measures. Infect. Dis. Clin. North Am., 1989, 4, 901-913.
8. [8] Muder, R. R., Brennen, C. and Wagener, M. M. et al., Methicillin-resistant staphylococcal colonization and infection in a long-term care facility. Ann. Int. Med., 1991, 114, 107-112.
9. [9] Boyce, J. M., White, R. L., Causey, W. A. and Lockwood, W. R., Burn units as a source of methicillin-resistant Staphylococcus aureus infections. JAMA, 1983, 20, 2803-2807.
10. [10] Blumberg, H. M., Rimland, D., Carroll, D. J., Terry, P. and Wachsmuth, I. K., Rapid development of ciprofloxacin resistance in methicillin-susceptible and -resistant Staphylococcus aureus. J. Infect. Dis., 1991, 63, 1279-1285.
11. [11] Neu, H. C., The crisis in antibiotic resistance. Science, 1992, 257, 1064-1073.
12. [12] Gold, H. S. and Moellering, R. C. Jr., Antimicrobial-drug resistance. Drug Ther., 1996, 335, 1445-1453.
13. [13] Handwerger, S., Raucher, B. and Altarac, D. et al., Nosocomial outbreak due to Enterococcus faecium resistant to vancomycin, penicillin, and gentamicin. J. Clin. Infect. Dis., 1993, 16, 750-755.
14. [14] Vemuri, R. K. and Zervos, M. J., Enterococcal infections: the increasing threat of nosocomial spread and drug resistance. Postgrad. Med., 1993, 93, 121-128.
15. [15] Iwen, P. C., Kelly, D. M. and Linder, J. et al., Change in prevalence and antibiotic resistance of Enterococcus species isolated from blood cultures over an 8-year period. Antimicrob. Agents Chemother., 1997, 41, 494-495.
16. [16] Eliopoulos, G. M., Increasing problems in the therapy of enterococcal infections. Eur. J. Clin. Microbiol. Infect. Dis., 1993, 12, 409-412.
17. [17] Shay, D. K., Goldmann, D. A. and Jarvis, W. R., Reducing the spread of antimicrobial-resistant microorganisms. Ped. Clinics North Am., 1995, 42, 703-716.
18. [18] Spera, R. V. and Farber, B. F., Multidrug-resistant Enterococcus faecium. Drugs, 1994, 48, 678-688.
19. [19] Rybak, M. J. and Palmer, S. M., Vancomycin-resistant enterococci. Pharmacother., 1995, 5, 684-685.
20. [20] CDC Recommendations for preventing the spread of vancomycin resistance, Recommendations of the Hospital Infection Control Practice Advisory Committee (HICPAC). MMWR 1994; 44/NORR12: 1-13.
21. [21] Smith, D. J. Jr. and Thompson, P. D., Changing flora in burn and trauma units: Historical perspective - experience in the United States. J. Burn Care Rehab., 1992, 13, 276-280.
22. [22] Law, E. J., Blecher, K. and Still, J. M., Enterococcal infections as a cause of mortality and morbidity in patients with burns. J. Burn Care Rehab., 1994, 15, 236-239.
23. [23] Vindenes, H. and Bjerknes, R., Microbial colonization of large wounds. Burns, 1995, 21, 575-579.
24. [24] Zellweger, G., Simmen, J. P., Meyer, V. E. and Kayser, F. H., Infection in the upper body: Hand and burn-wound microbiology and considerations for antimicrobial therapy. J. Burn Care Rehab., 1992, 13, 298-304.
25. [25] Leclercq, R. and Courvalin, P., Resistance to glycopeptides in enterococci. Clin. Infect. Dis., 1997, 24, 545-546.
26. [26] Uttley, A. H. C., Collins, C. H., Naidoo, J. and George, R. C., Vancomycin-resistant enterococci. Lancet, 1988, 1, 57
27. [27] Leclercq, R., Derlot, E. and Weber, M., Transferable vancomycin and teicoplanin resistance in Enterococcus faecium. Antimicrob. Agents Chemother., 1989, 33, 10-15.
28. [28] Sanyal, D., Johnson, A. P., George, R. C., Cookson, B. D. and William, A. J., Peritonitis due to vancomycin-resistant Staphylococcus epidermidis. Lancet, 1991, 337, 54
29. [29] Heaton, M. P., Discotto, L. F., Pucci, M. J. and Handwerger, S., Mobilization of vancomycin resistance by transposon-mediated fusion of a vanA plasmid with an Enterococcus faecium sex pheromone-response plasmid. Gene, 1996, 171, 9-17.
30. [30] Noble, W. C., Virani, Z. and Cree, R., Co-transfer of vancomycin and other resistance genes from Enterococcus faecalis NCTC12201 to Staphylococcus aureus. FEMS Microbiol. Lett., 1992, 93, 195-198.
31. [31] Veach, L. A., Pfaller, M. A. and Barrett, M., Vancomycin resistance in Staphylococcus haemolyticus causing colonization and bloodstream infection. J. Clin. Microbiol., 1990, 28, 2064-2068.
32. [32] Degener, J. E., Heck, M. E. O. C. and Vanleeuwen, W. J., Nosocomial infection by Staphylococcus haemolyticus and typing methods of epidemiological study. J. Clin. Microbiol., 1994, 32, 2260-2265.
33. [33] Daum, R. S., Gupta, S., Sabbagh, R. and Milewski, W. M., Characterization of Staphyloccus aureus isolates with decreased susceptibility to vancomycin and teicoplainin: Isolation and purification of a constitutively produced protein associated with decreased susceptibility. J. Infect. Dis., 1992, 166, 1066-1072.
34. [34] Holder, I. A., Gentamicin resistant Pseudomonas aeruginosa in a burns institute. J. Antimicrob. Chemother., 1976, 2, 309-310.
35. [35] Peacock, J. E. Jr., Marsik, F. J. and Wenzel, R. P., Methicillin-resistant Staphylococcus aureus: Introduction and spread within a hospital. Ann. Int. Med., 1980, 93, 526-532.
36. [36] Crossley, K., Loesch, D., Landesman, B., Mead, K., Chern, M. and Strate, R., An outbreak of infections caused by strains of Staphylococcus aureus resistant to methicillin and aminoglycosides I. Clinical studies. J. Infect. Dis., 1979, 139, 273-279.
37. [37] Boyce, J. M., Landry, M., Deetz, T. R. and DuPont, H. L., Epidemiologic studies of an outbreak of nosocomial methicillin-resistant Staphylococcus aureus infections. Infect. Control, 1981, 2, 110-116.
38. [38] Shannon T., Edgar P., Villarreal C., Herndon D. N., Phillips L. G., Heggers J. P. Much ado about nothing: MRSA. J. Burn Care Rehab. 1997; 18: in press.
39. [39] McManus, A. T., Mason, A. D. Jr., McManus, W. F. and Pruitt, B. A. Jr., What's in a name? Is methicillin-resistant Staphylococcus aureus just another S. aureus when treated with vancomycin?. Arch. Surg., 1989, 124, 1456-1459.
40. [40] Recommendations for preventing the spread of vancomycin resistance: From the Hospital Infection Control Practices Advisory Committee (HICPAC). Drug Benefit Trends 1996; 8: 22-27.
41. [41] Small, P. M. and Chambers, H. F., Vancomycin for Staphylococcus aureus endocarditis in intravenous drug users. Antimicrob. Agents Chemother., 1990, 34, 1227-1231.
42. [42] Cantoni, L., Glauser, M. P. and Bille, J., Comparative efficacy of daptomycin, vancomycin, and cloxacillin for the treatment of Staphylococcus aureus endocarditis in rats and role of test conditions in this determination. Antimicrob. Agents Chemother., 1990, 34, 2348-2353.
43. [43] Conte, J. E. Jr., Cohen, S. N. and Roe, B. B. et al. Antibiotic prophylaxis and cardiac surgery: A prospective double-blind comparison of single-dose versus multiple-dose regimens. Ann. Int. Med., 1972, 76, 943-949.
44. [44] Rubin, M., Hathorn, J. W. and Marshall, D. et al., Gram-positive infections and the use of vancomycin in 550 episodes of fever and neutropenia. Ann. Int. Med., 1988, 108, 30-35.
45. [45] Shenep, J. L., Hughes, W. T. and Roberson, P. K. et al., Vancomycin, ticarcillin, and amikacin compared with ticarcillin-clavulanate and amikacin in the empirical treatment of febrile neutropenic children with cancer. New Engl. J. Med., 1988, 319, 1053-1058.
46. [46] Pizzo, P. A., Hathorn, J. W. and Hiemenz, J. et al., A randomized trial comparing ceftazidime alone with combination antibiotic therapy in cancer patients with fever and neutropenia. New Engl. J. Med., 1986, 315, 552-558.
47. [47] Karp, J. E., Dick, J. D. and Angelopulos, C. et al., Empiric use of vancomycin during prolonged treatment-induced granulocytopenia: Randomized, double-blind, placebo-controlled clinical trial in patients with acute leukemia. Am. J. Med., 1986, 81, 237-242.
48. [48] European Organization for Research and Treatment of Cancer (EORTC) International Antimicrobial Therapy Cooperative Group, National Cancer Institute of Canada Clinical Trials Group. Vancomycin added to empirical combination antibiotic therapy for fever in granulocytopenic cancer patients. J. Infect. Dis. 1991; 163: 951-958.
49. [49] Riikonen, P., Imipenem compared with ceftazidime plus vancomycin as initial therapy for fever in neutropenic children with cancer. Ped. Infect. Dis., 1991, 10, 918-923.
50. [50] Lamy, T., Michelet, C. and Dauriac, C. et al., Benefit of prophylaxis by intravenous systemic vancomycin in granulocytopenic patients: A prospective, randomized trial among 59 patients. Acta Haematol., 1993, 90, 109-113.
51. [51] Isaacman, D. J. and Karsic, R. B., Lack of effect of changing needles on contamination of blood cultures. Ped. Infect. Dis. J., 1990, 9, 274-278.
52. [52] Krumholz, H. M., Cummings, S. and York, M., Blood culture phlebotomy: Switching needles does not prevent contamination. Ann. Int. Med., 1990, 113, 290-292.
53. [53] Strand, C. L., Wajsbort, R. R. and Sturmann, K., Effect of iodophor vs. iodine tincture skin preparation on blood culture contamination rate. JAMA, 1993, 269, 1004-1006.
54. [54] Maki, D. G. and Schuna, A. A., A study of antimicrobial misuse in a university hospital. Am. J. Med. Sci., 1978, 275, 271-282.
55. [55] Ranson, M. R., Oppenheim, B. A. and Jackson, A. et al., Double-blind placebo-controlled study of vancomycin prophylaxis for central venous catheter insertion in cancer patients. J. Hosp. Infect., 1990, 15, 95-102.
56. [56] Henrickson, K. J., Powell, K. R. and Schwartz, C. L., A dilute solution of vancomycin and heparin retains antibacterial and anticoagulant activities. J. Infect. Dis., 1988, 157, 600-601.
57. [57] Schwartz, C., Henrickson, K. J. and Roghmann, K. et al., Prevention of bacteremia attributed to luminal colonization of tunneled central venous catheters with vancomycin-susceptible organism. J. Clin. Oncol., 1990, 8, 1591-1597.
58. [58] Henrickson, K. J. and Dunne, W. M. Jr., Modification of central venous catheter flush solution improves in vitro antimicrobial activity. J. Infect. Dis., 1992, 166, 944-946.
59. [59] Gaillard, J. L., Merlino, R. and Pajot, N. et al., Conventional and nonconventional modes of vancomycin administration to decontaminate the internal surface of catheters colonized with coagulase-negative staphylococci. J. Paren. Enter. Nutr., 1990, 14, 593-597.
60. [60] Spafford, P. S., Sinkin, R. A. and Cox, C. et al., Prevention of central venous catheter-related coagulase-negative staphylococcal sepsis in neonates. J. Pediatr., 1994, 125, 259-263.
61. [61] Kaplan, A. H., Gilligan, P. H. and Facklam, R. R., Recovery of resistant enterococci during vancomycin prophylaxis. J. Clin. Microbiol., 1988, 26, 1216-1218.
62. [62] Gradon, J. D., Wu, E. H. and Lutwick, L. I., Aerosolized vancomycin therapy facilitating nursing home placement. Ann. Pharmacother., 1992, 26, 209-210.
63. [63] Weathers, L., Riggs, D. and Santeiro, M. et al., Aerosolized vancomycin for treatment of airway colonization by methicillin-resistant Staphylococcus aureus. Ped. Infect. Dis., 1990, 9, 220-221.
64. [64] Johnson, S., Homann, Sr. and Bettin, K. M. et al., Treatment of asymptomatic Clostridium difficile carriers (fecal excretors) with vancomycin or metronidazole. Ann. Int. Med., 1992, 117, 297-302.
65. [65] Bastani, B., Freer, K. and Read, D. et al., Treatment of grampositive peritonitis with two intraperitoneal doses of vancomycin in continuous ambulatory peritoneal dialysis patients. Nephron, 1987, 45, 283-285.
66. [66] Newman, L. N., Tessman, M. and Hanslik, T. et al., A retrospective view of factors that affect catheter healing: Four years of experience. Adv. Perit. Dial., 1993, 9, 217-222.
67. [67] Capdevila, J. A., Segarra, A. and Planes, A. M. et al., Successful treatment of haemodialysis catheter-related sepsis without catheter removal. Nephrol. Dial. Transplant, 1993, 8, 231-234.
68. [68] Edell, L. S., Westby, G. R. and Gould, S. R., An improved method of vancomycin administration to dialysis patients. Clin. Nephrol., 1988, 29, 86-87.